RU94042935A - Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав - Google Patents

Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав

Info

Publication number
RU94042935A
RU94042935A RU94042935/04A RU94042935A RU94042935A RU 94042935 A RU94042935 A RU 94042935A RU 94042935/04 A RU94042935/04 A RU 94042935/04A RU 94042935 A RU94042935 A RU 94042935A RU 94042935 A RU94042935 A RU 94042935A
Authority
RU
Russia
Prior art keywords
water
complexes
soluble
cyclodextrines
preparing
Prior art date
Application number
RU94042935/04A
Other languages
English (en)
Other versions
RU2135176C1 (ru
Inventor
Ульман Брайант Генри
Us]
Джозеф Каллинан Джордж
Клифтон Фрэнсиз Пол
Эдвард Мэджи Дэвид
Энн Свитена Стефания
Лэвджи Тэккер Эрвинд
In]
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94042935A publication Critical patent/RU94042935A/ru
Application granted granted Critical
Publication of RU2135176C1 publication Critical patent/RU2135176C1/ru

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Изобретение относится к водным комплексам включения некоторых известных бензотиофеновых соединений, в частности ралоксифена, а также водорастворимых циклодекстринов. Кроме того, предлагаются фармацевтические композиции таких комплексов включения и способы применения этих комплексов для ингибирования усыхания кости и уменьшения сывороточного холестерина у млекопитающих.

Claims (1)

  1. Изобретение относится к водным комплексам включения некоторых известных бензотиофеновых соединений, в частности ралоксифена, а также водорастворимых циклодекстринов. Кроме того, предлагаются фармацевтические композиции таких комплексов включения и способы применения этих комплексов для ингибирования усыхания кости и уменьшения сывороточного холестерина у млекопитающих.
RU94042935A 1993-12-14 1994-12-06 Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция RU2135176C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16678893A 1993-12-14 1993-12-14
US08/166788 1993-12-14
US08/166,788 1993-12-14

Publications (2)

Publication Number Publication Date
RU94042935A true RU94042935A (ru) 1997-01-10
RU2135176C1 RU2135176C1 (ru) 1999-08-27

Family

ID=22604709

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042935A RU2135176C1 (ru) 1993-12-14 1994-12-06 Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция

Country Status (27)

Country Link
US (1) US5624940A (ru)
EP (1) EP0658348B1 (ru)
JP (1) JPH07196495A (ru)
KR (1) KR950017949A (ru)
CN (1) CN1109751A (ru)
AT (1) ATE205726T1 (ru)
AU (1) AU689817B2 (ru)
BR (1) BR9404936A (ru)
CA (1) CA2137533A1 (ru)
CO (1) CO4340621A1 (ru)
CZ (1) CZ306394A3 (ru)
DE (1) DE69428334T2 (ru)
DK (1) DK0658348T3 (ru)
ES (1) ES2160615T3 (ru)
FI (1) FI945839A (ru)
HU (1) HUT72298A (ru)
IL (1) IL111930A0 (ru)
NO (1) NO944764L (ru)
NZ (1) NZ270077A (ru)
PE (1) PE36795A1 (ru)
PH (1) PH31265A (ru)
PL (1) PL306173A1 (ru)
PT (1) PT658348E (ru)
RU (1) RU2135176C1 (ru)
SI (1) SI0658348T1 (ru)
YU (1) YU72594A (ru)
ZA (1) ZA949715B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US6180075B1 (en) 1997-04-09 2001-01-30 Degussa-H{umlaut over (u)}ls Aktiengesellschaft Exhaust gas catalyst
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US20030232068A1 (en) * 2002-06-14 2003-12-18 Lewandowski Daniel J. Food product having increased bile acid binding capacity
US20040157096A1 (en) * 2002-10-07 2004-08-12 Peterson Richard B. Plug-compatible modular thermal management packages
US20040116382A1 (en) * 2002-12-13 2004-06-17 Plank David W. Food products containing cyclodextrins having beneficial hypocholesterolemic effects and method of making and communicating the benefit of such products
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
US20040180125A1 (en) * 2003-03-11 2004-09-16 Plank David W. Cyclodextrin-containing compositions and methods
US7335386B2 (en) * 2003-07-30 2008-02-26 Gerneral Mills, Inc. Method for preventing acrylamide formation in food products and food intermediates
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
AU2004229291A1 (en) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
US7442720B2 (en) 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US20090318560A1 (en) * 2007-02-26 2009-12-24 Wayne Parent Formulations for cathepsin k inhibitors
EP2253627A1 (en) * 2009-05-21 2010-11-24 ERREGIERRE S.p.A. Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.
CN102198274B (zh) * 2011-03-30 2013-04-24 天津红日药业股份有限公司 雷洛昔芬的环糊精包合物及其制剂的制备方法
ITMI20121821A1 (it) * 2012-10-25 2014-04-26 Erregierre Spa Composizione farmaceutica solubile in acqua a base di un sale di raloxifene

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
HU181703B (en) * 1980-05-09 1983-11-28 Chinoin Gyogyszer Es Vegyeszet Process for producing aqueus solutuins of water insoluble or hardly soluble vitamines, steroides, localanesthetics, prostanoides and non-steroid and antiphlogistic agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
HU199444B (en) * 1985-09-10 1990-02-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 7-isopropoxy-isoflavone-cyclodextrene inclusion complex and pharmaceutical compositions therefrom
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
GB8814725D0 (en) * 1988-06-21 1988-07-27 Glaxo Group Ltd Medicaments
NL8801670A (nl) * 1988-07-01 1990-02-01 Walter Adrianus Josephus Johan Farmaceutisch preparaat.
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
JPH02279631A (ja) * 1989-04-18 1990-11-15 Yamanouchi Pharmaceut Co Ltd 薬物のシクロデキストリン包接体及びその製造法
JPH02300140A (ja) * 1989-05-12 1990-12-12 Yamanouchi Pharmaceut Co Ltd 薬物のシクロデキストリン包接体及びその製造法
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5101065A (en) * 1991-02-04 1992-03-31 Imperial Chemical Industries Plc Acetophenone intermediates
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
CN1109751A (zh) 1995-10-11
CA2137533A1 (en) 1995-06-15
RU2135176C1 (ru) 1999-08-27
EP0658348A2 (en) 1995-06-21
PH31265A (en) 1998-06-18
NO944764D0 (no) 1994-12-08
ES2160615T3 (es) 2001-11-16
FI945839A0 (fi) 1994-12-12
DK0658348T3 (da) 2001-11-12
ATE205726T1 (de) 2001-10-15
YU72594A (sh) 1997-07-31
HU9403567D0 (en) 1995-02-28
PT658348E (pt) 2002-02-28
NZ270077A (en) 1996-04-26
CZ306394A3 (en) 1995-08-16
KR950017949A (ko) 1995-07-22
AU689817B2 (en) 1998-04-09
DE69428334T2 (de) 2002-06-20
EP0658348A3 (en) 1996-08-07
IL111930A0 (en) 1995-03-15
HUT72298A (en) 1996-04-29
ZA949715B (en) 1996-06-06
SI0658348T1 (en) 2002-06-30
NO944764L (no) 1995-06-15
US5624940A (en) 1997-04-29
DE69428334D1 (de) 2001-10-25
EP0658348B1 (en) 2001-09-19
PE36795A1 (es) 1995-11-06
FI945839A (fi) 1995-06-15
AU8033594A (en) 1995-06-22
JPH07196495A (ja) 1995-08-01
BR9404936A (pt) 1995-08-08
CO4340621A1 (es) 1996-07-30
PL306173A1 (en) 1995-06-26

Similar Documents

Publication Publication Date Title
RU94042935A (ru) Водорастворенные комплексы включения соединений бензотиофена с водорастворимыми циклодекстринами, способ их получения и фармацевтический состав
BR9809481A (pt) Composto, processo para sua preparação, uso do mesmo, composição farmacêutica, e, processos para sua preparação, para efetuar a imunossupressão e para tratar ou reduzir o risco de uma doença obstrutiva reversìvel das vias aéreas em um paciente
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
BR9811818A (pt) Uso de um composto, composto, e, composição farmacêutica
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
AU561016B2 (en) N-glycosylated carboxamide derivatives
ES2085920T3 (es) Liposomas dirigidos y metodos de acoplamiento liposoma-proteina.
RU95106821A (ru) Циклопептиды, способ их получения, фармацевтическая композиция и способ ее получения
RU95110937A (ru) Хинолоновые и акридиноновые соединения, способ их получения, фармацевтическая композиция и промежуточные соединения
ATE426402T1 (de) Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l
KR960022542A (ko) 광학 활성 벤조티에핀 유도체, 그의 제조방법 및 용도
RU94038256A (ru) Производные пиразолопиримидина, способ их получения, фармацевтические композиции на их основе
RU94044534A (ru) Амино-производные тиазола, способы их получения и содержащие их фармацевтические композиции
JPS61155324A (ja) 癌治療薬剤
ZA90962B (en) Phenylhydrazones,the manufacture thereof and therapeutic and cosmetic compositions prepared therefrom
AU567018B2 (en) Prazosin-pirbuterol combination for bronchoduation
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
PT98538A (pt) Processo de preparacao de factor de crescimento humano epidermico (hegf) dos seus congeneres e de composicoes farmaceuticas que os contem
BR9908387A (pt) Processo de preparação de derivados de 5-imino-13-deoxiantraciclina, respectivos compostos e composição farmacêutica e método de tratamento de câncer, doenças autoimunes ou desordens de imunodeficiência
KR920700669A (ko) 치료시 비사이클릭 화합물의 n-이미다졸릴 유도체 및 사이클로스포린의 혼합 용도
RU94016314A (ru) Способ пластики-задне-боковой стенки реконструированной гортани
RU94008752A (ru) Производные 3-ароилбензо(в)-тиофена, фармацевтическая композиция на их основе